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Abstract
Background: In developing countries, renal specialists are scarce and physician-to-patient contact time is limited.
While conventional hospital-based, physician-oriented approach has been the main focus of chronic kidney disease
(CKD) care, a comprehensive multidisciplinary health care program (Integrated CKD Care) has been introduced as
an alternate intervention to delay CKD progression in a community population. The main objective is to assess
effectiveness of Integrated CKD Care in delaying CKD progression.
Methods: We carried out a community-based, cluster randomized controlled trial. Four hundred forty-two stage 3-4 CKD
patients were enrolled. In addition to the standard treatments provided to both groups, the patients in the intervention
group also received “Integrated CKD Care”. This was delivered by a multidisciplinary team of hospital staff in conjunction
with a community CKD care network (subdistrict healthcare officers and village health volunteers) to provide group
counseling during each hospital visit and quarterly home visits to monitor compliance with the treatment. Duration of
the study was 2 years. The primary outcome was difference of mean eGFR between the intervention and the control
groups over the study period.
Results: The mean difference of eGFR over time in the intervention group was significantly lower than the control group
by 2.74 ml/min/1.73 m2 (95%CI 0.60–4.50, p = 0.009). Seventy composite clinical endpoints were reported during the
study period with significantly different incidences between the control and the intervention groups (119.1 versus 69.4
per 1000 person-years; hazard ratio (HR) 0.59, 95% CI 0.4–0.9, p= 0.03).
Conclusion: Integrated CKD Care can delay CKD progression in resource-limited settings.
Trial registration: (NCT01978951). Prospectively registered as of December 8, 2012.
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Background
Chronic Kidney Disease (CKD) is a global public health
problem, strongly associated with increased risk of
death, cardiovascular events, and hospitalization [1–3].
Despite several guidelines, its prevalence is still high in
developing countries [4]. A recent community-based
survey in Thailand revealed that the prevalence of stage
3–5 CKD was 8.8% [5]. The total number of pre-dialysis
CKD patients in Thailand has been estimated at 4.1 mil-
lion, which is impossible for the currently available 450
nephrologists to deal with. This nephrologist-to-patient
ratio of 1:15,000 indicated that traditional physician-
based approach is inadequate for ensuring equitable
access to CKD care, even under the currently successful
Universal Coverage scheme. With limited national re-
sources, delaying the progression of CKD from early to
advance stages is essential for efficient utilization of the
limited number of nephrologists at minimizing health-
care cost. As patients residing in rural areas are less
likely to reach well-qualified personnel when compared
with city dwellers [6], it is mandatory to seek other ap-
propriate forms of renal care to delay CKD progression.
Reorienting service delivery to focus on primary care
and more efficient use of healthcare professionals other
than nephrologists has been one of the promising solu-
tions. Recent evidence suggested that a comprehensive
intervention by nurse practitioners supervised by a
qualified nephrologist could reduce the risk of cardiovas-
cular events among diabetic patients as well as attenuate
the decline of kidney function and improve the renal
outcomes in CKD patients [7–9].
Thai patients have enjoyed the unique primary health
service delivery system in which health care officers at
subdistrict level collaborated very well with village
health volunteers (VHVs). The VHVs are villagers vol-
untarily recruited from their own villages to become
key bridging points between subdistrict health and
non-health systems. Approximately one million VHVs
have covered more than 90% of all villages and there-
fore have become the backbone of community-based
public health service in Thailand. This system has been
so successful that Thailand was regarded as one of a
few developing countries that have an efficient primary
health care service [10–13].
Should the primary health care officers and VHVs be
trained to render proper CKD care, it would be interesting
to examine whether their intimate relationship and com-
mitment to their responsible village households will result
in better outcomes than the conventional physician-based
care. Evidence on the effectiveness of this type of compre-
hensive multidisciplinary intervention in developing coun-
tries has been lacking. One reason might be that this type
of complicated intervention has been developed naturally
out of initiatives of different stakeholders. Our attempt to
clearly define the intervention allowed for further investi-
gation of the outcomes.
This study was aimed to compare the effectiveness on
delaying CKD progression between a conventional and an
integrated CKD care (ICC) provided by a multidisciplinary
care team (MDCT) of hospital staffs in conjunction with
the a community CKD care network (CCN, subdistrict
health care officers and VHVs).
Methods
Study design
The ESCORT study (Effectiveness of Integrated Care
on Delaying Progression stage 3–4 Chronic Kidney
Disease in Rural Communities of Thailand) is a
community-based, cluster randomized controlled trial.
The rationale and design of this 2-year study was pub-
lished elsewhere [14]. In brief, participants were stage
3-4 CKD patients, 18–70 years of age, and had diabetes
and/or hypertension. They lived in the two randomized
districts in Kamphang Phet province located 400 km
north of Bangkok, Thailand. Of 11 districts in the prov-
ince, two districts were randomly selected. Then, of the
total of Stage 3-4 CKD patients in each district, 586 pa-
tients were assessed for eligibility and 442 participants
were randomly selected to the study. Next, participants
of each group will be further subdivided into 12 patient
subgroups according to the area of their sub districts,
resulting in 25–30 CKD patients per subgroup. During
enrollment period, 94 cases were excluded as per exclu-
sion criteria and 50 cases refused to participate. Those
with unstable/advanced cardiovascular diseases, ob-
structive uropathy, HIV infection, pregnancy, body
mass index (BMI) less than 18 or more than 40 kg/m2,
untreated malignancy, urine protein-creatinine ratio
exceeded 3.5 g/g creatinine, or active urinary sediments
(red or white blood cells more than three and 10 cells/
high power field, respectively) were excluded. The study
had been conducted for 24 consecutive months (June
2011–July 2013).
Interventions
Baseline information including past medical history,
physical examination, and medications as well as blood
and urine samples were collected from all subjects.
While patients in both intervention and control groups
received standard clinical care and medications as well
as group-based educational programs during their visit
to the district hospital, the intervention group also re-
ceived the Integrated CKD Care program described
below.
Integrated CKD care program
The Integrated CKD Care (ICC) program is operated by
[1] a multidisciplinary care team (MDCT) of the
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respective district hospital, consisting of two general
practitioners, two chronic care nurses, one pharmacist,
one nutritionist, one physical therapist and [2] commu-
nity care network (CCN) teams, each consists of one
subdistrict health care officer, 3–5 village health volun-
teers (VHVs), and selected family members of the CKD
patients residing in the respective patient subdistrict.
Instead of routine care, MDCT provided systematically
comprehensive medical care and educational activities,
including live demonstration of optimal diets, medica-
tion, and advice on exercise for CKD patients in each
visit to the hospital. A 4-day CKD care training-course
was organized for CCN members prior to study com-
mencement. The course offered basic knowledge of
CKD, NKF-K/DOQI guidelines, and optimal diet for
CKD patients [15]. The content of basic medical know-
ledge was simplified to match with the educational level of
CCN members. Dietitian [A.S.] provided essential know-
ledge about collection and interpretation methods of
modified 24-h dietary recalls or Easy Dietary Assessment
tool (EDA) [16]. In addition, each subgroup of CCN pro-
vided home visits to their respective patients at 6–8 weeks
after each hospital visit. Four main assessments were done
during each home visit: 24-h dietary recalls, blood pres-
sure measurement, medication compliance monitoring
including avoidance of nephrotoxic agents (e.g. non-
steroidal anti-inflammatory drugs), and exercise behavior.
Details of clinical intervention during hospital and home
visits of both groups were reported elsewhere [14].
Laboratory analysis
All patients were scheduled to follow-up clinical and
laboratory parameters at their respective district hospi-
tals at 3-month intervals. All blood and urine samples
were analyzed with ABX Pentra 400 analyzer (HORIBA
ABX S.A.S., France) located at these hospitals. All bio-
chemistry analyses were validated according to the stand-
ard protocol of Department of Medical Sciences, Ministry
of Public Health, Thailand. Serum creatinine was mea-
sured by the enzymatic method. It was standardized with
standard reference material (SRM 967) by commutability
study every 6 months [17]. Two out of twelve subgroups
of both patient groups were randomly selected and
assigned to collect 24-h urine urea nitrogen and sodium.
Outcomes
The primary outcome of this study was the difference of
mean eGFR between the two groups over the study
period, measured by creatinine-based CKD-EPI equation
[18]. The secondary outcomes were laboratory parameters
and incidence of clinical endpoints including mortality,
cardiovascular events (acute myocardial infarction and
stroke), ESRD (eGFR is less than 15 ml/min/1.73 m2), and
50% increase in serum creatinine from baseline. In this
study, acute myocardial infarction was defined as symp-
toms of chest pain, new ischemic pattern change of ECG
and significant rising of cardiac enzymes. Acute stroke
was defined as a clinically significant neurological deficit
with radiographic evidence. Patients were seen at the first
month and followed every 3 months afterwards for 2
years. Quality of life was assessed using the validated Thai
SF-36 questionnaire [19].
Statistical analysis
The primary outcome was analyzed based on an intention-
to-treat basis. We use generalized estimating equations
(GEE), adjusted for age, gender, diabetes, and hypertension,
to analyze continuous variables in both primary and sec-
ondary outcomes [20]. To apply the primary outcome to
real-life clinical practice, we also analyzed rate of eGFR de-
cline based on assumption that the change was in linear
pattern. The differences of rate of eGFR decline were ana-
lyzed using a linear mixed effects model, with random in-
tercepts and slopes. The differences of incidence of clinical
endpoints were analyzed using Cox-proportional-hazard
models, involving survival time to the first relevant clinical
endpoint in any individual patients. In this analysis, data
were censored the date of last visit of patients who loss to
follow-up or withdrew from the study. Descriptive statistics
such as unpaired Student t-test and chi-square test were
used to compare mean values and categorical data respect-
ively. All statistical tests were two-tailed, using a p-value of
less than 0.05 as being statistically significant. The data was
analyzed using SPSS 16.0 (SPSS Inc., Chicago, IL, USA).
Results
Findings from this study are reported according to
CONSORT guidelines [21]. Four hundred and forty-two
participants met the enrollment criteria, and were in-
cluded into the intervention (234 cases) and control
(208 cases) groups (Fig. 1). The main reasons of non-
participation (94 cases) were inability to attend the pro-
posed visits, changing point of care to another hospital
outside the study region and failure to contact the pa-
tients. The study was completed in July 2013 with 24-
month median follow-up time. Sixteen patients (3.6%)
were lost to follow-up, eight patients (1.8%) withdrew
from the study. Most of baseline clinical and laboratory
characteristics, including eGFR, of the two groups were
comparable; however, the levels of HbA1c, 24-h urine
sodium and normalized Protein Nitrogen Appearance
(nPNA) of the control group were slightly higher than
intervention group (Table 1).
Effectiveness of integrated CKD care on rate of eGFR decline
In adjusted analysis, the mean difference of eGFR over
time in the intervention group was significantly lower
than the control group 2.74 ml/min/1.13 m2 (95%CI
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0.60–4.50, p = 0.009) (Fig. 2). The rate of eGFR decline
in the control group and the intervention group were
(−2.0) ml/min/1.73 m2 per year and 0.09 ml/min/
1.73 m2 per year, respectively. The rate of eGFR decline
of the intervention group was significantly lower than
the control group by 2.1 ml/min/1.73 m2 per year (95%
confidence interval (−2.8)–(−1.2), p = 0.001).
Effectiveness of integrated CKD care on cardiovascular
risk factors and medication use
Table 2 shows the analysis of secondary outcomes, the
mean values during follow-up and mean difference at the
end of the study of several parameters of the intervention
group were significantly lower than the control group with
respect to HbA1C, serum triglycerides, 24-h urine Na, and
24-h urine nPNA. On the contrary, mean values during
follow-up and mean difference of systolic and diastolic
blood pressure as well as serum bicarbonate of control
group were significantly lower than that of the intervention
group. Urine protein-creatinine ratio and LDL-cholesterol
levels of the two groups were comparable (Fig. 3).
At baseline, the number of antihypertensive drugs pre-
scribed, the percentage of patients receiving ACEI/ARBs,
lipid-lowering agents, insulin, and non-steroidal anti-
inflammatory drugs (NSAIDs) use were comparable be-
tween the two groups (Table 3). However, the percentage
of patients in control group who received aspirin was
significantly higher than the intervention group (63.9%
vs. 36.3%, p = 0.03). At the end of the follow-up period,
more patients in the intervention group received insulin
than the control group (28.4% vs. 16.9%, p = 0.01). The
percentages of medications use in the intervention group
were higher than the control group but not statistically
significant.
Effectiveness on clinical endpoints
Seventy composite clinical endpoints were reported dur-
ing the study period (Table 4) with significantly different
incidences between the control and the intervention
groups (119.1 versus 69.4 per 1000 person-years; hazard
ratio (HR) 0.59, 95% CI 0.4–0.9, p = 0.03). There were
no significant differences in quality of life between the
two groups (results not shown).
Discussion
This is the first, large scale, community-based randomized
controlled trial evidence demonstrating that comprehen-
sive community-based intervention by multidisciplinary
care team in conjunction with a community care network
teams of non-healthcare members can slow the rate of
eGFR decline and is feasible and in CKD patients residing
in resource-limited settings. Given similar medical care
between the two groups including medication in particular
ACEi/ARBs and educational materials, our study demon-
strated that integrated CKD care significantly improved
several clinical parameters with respect to serum bicar-
bonate levels, 24-h urine nPNA, 24-h urine Na, HbA1C,
and serum triglyceride levels. Each parameter had been
proven effectiveness on delaying CKD progression or low-
ering cardiovascular events by single-factorial intervention
studies [22–27]. In other words, we may imply that the
key factors in delaying CKD progression of Integrated
CKD Care were improvement of compliance with
medication and dietary control. Consequently, this
intervention seems to improve some non-conventional
cardiovascular risk factors and may contribute to im-
provement of composite clinical endpoints. We expect
the results of this study will set forth a new standard of
Fig. 1 Flow chart of participants. Abbreviation: ESRD, End-stage renal disease
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community-based CKD care for Thailand and other
resource-limited countries.
According to the results of several landmark studies, the
key mechanisms that could improve clinical outcomes and
delay rate of eGFR decline are optimization of traditional
cardiovascular risk management. Gæde P, et al. (STENO2
study) demonstrated that a long-term (mean, 7.8 years), in-
tensified multifactorial intervention in a specialized diabetes
clinic, which targeted on blood pressure <130/80 mmHg,
glycosylated hemoglobin <6.5%, triglycerides <150 mg/dL,
and ACEi and Aspirin use, could significantly reduce risk of
cardiovascular disease (HR 0.47; 95%CI 0.24–0.73) and
nephropathy (HR 0.39; 95%CI 0.17–0.87) among patients
with type 2 diabetes and microalbuminuria [7]. Peeters MJ,
et al. (MASTERPLAN study) proposed that significantly
improved rate of eGFR decline after 2 years of follow-up
was mainly related to better BP control, increased use of
ACEIs/ARBs, reduction of proteinuria, and possibly in-
creased use of active Vitamin D [8]. On the contrary, our
study revealed a different perspective of CKD treatments.
At the baseline, mean systolic and diastolic blood pressure
of the control and the intervention groups were not statisti-
cally different. Then during the study period, despite using
the same treatment guidelines and medication, mean BP
Table 1 Baseline characteristics of participants
Control (n = 208) Intervention (n = 234) P-value
Age (years) 62.4 ± 7.9 62.3 ± 6.4 0.89
Female (%) 152 (73.1%) 170 (72.6%) 0.92
Educational status
Elementary school or lower (%) 205 (98.6) 217 (92.7) 0.09
BMI 25.0 ± 5.5 25.7 ± 7.9 0.32
Systolic BP (mmHg) 123.8 ± 16.9 125.9 ± 15.6 0.19
Diastolic BP (mmHg) 75.6 ± 2.8 76.7 ± 2.9 0.22
Smoking (%) 7 (3.4) 4 (1.7) 0.23
Co-morbidities
DM (%) 108 (51.9) 129 (55.1) 0.50
HT (%) 192 (92.3) 210 (89.7) 0.35
History of IHD 11 (5.2) 11 (4.7) 0.44
History of CVA 2 (0.9) 6 (2.5) 0.07
Initial laboratory parameter
Creatinine (mg/dl) 1.53 ± 0.08 1.55 ± 0.07 0.21
eGFR (CKD-EPI, ml/min/1.73 m2) 41.8 ± 10.6 41.2 ± 10.3 0.32
UPCR (mg/g) 457.3 ± 700.3 442.4 ± 752.5 0.84
Hemoglobin (g/dl) 11.4 ± 2 11.6 ± 3.1 0.52
HbA1C 7.9 ± 2.4 7.3 ± 1.4 0.02
LDL (mg/dl) 113.9 ± 35.9 120.8 ± 38.5 0.06
Potassium (mEq/L) 4.6 ± 0.6 4.1 ± 0.6 0.04
Bicarbonate (mEq/L) 22.9 ± 3.7 25.4 ± 6.1 0.26
24-h u Na (mg/day) 4,485 ± 80 3,241 ± 55 0.02
24-h nPNA (g/kg/day) 1.08 ± 0.4 0.84 ± 0.2 0.01
Treatment
No. of antihypertensive medications 2.0 2.2 0.06
ACEi/ARBs (%) 190 (91.3) 199 (85) 0.05
Statin use (%) 156 (75.5) 167 (71.4) 0.33
NSAID (%) 32 (15.4) 45 (19.2) 0.08
Aspirin (%) 133 (63.9) 85 (36.3) 0.05
Data was shown as means (standard deviation) for continuous variables and percentages for categorical variables
Abbreviations: BMI Body Mass Index, BP Blood Pressure, DM Diabetes Mellitus, HT Hypertension, IHD Ischemic Heart Disease, CVA Cerebrovascular accident, eGFR
estimated Glomerular Filtration Rate, CKD-EPI the Chronic Kidney Disease Epidemiology Collaboration equation, UPCR Urine Protein-Creatinine Ratio, HbA1C HemoglobinA1C,
LDL Low-density Lipoprotein, nPNA normalized Protein Nitrogen Appearance, ACEi/ARBs Angiotensin Converting Enzyme inhibitors/Angiotensin Receptor Blockers, NSAIDs
Non-steroidal Antiinflammatory Drugs
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overtime of the control group was significantly lower than
the intervention group. However, when looking at the mean
BP overtime of the two groups, mean BP overtime of the
two groups, both of them were within therapeutic range.
Therefore, it would not be reasonable to interprete that
lowering blood pressure could be a potential reason that
contributes to the delaying of eGFR decline. Even though
the changes of some parameters such as blood pressure,
urine protein-creatinine ratio, and LDL-cholesterol levels
did not concur with findings from prior multifactorial
intervention studies, these parameters were within thera-
peutic targets according to standard guidelines.
Interestingly, it should be noted that baseline serum
bicarbonate level of the two groups was not significantly
different. In this study, we found that mean bicarbonate
levels over time of the control group were significantly
lower than the intervention group. Therefore, it might
be implied that optimization of serum bicarbonate level
could lead to the delaying of rate of eGFR decline
whether this was due to the intervention or not. This
Fig. 2 Changes in eGFR during the follow-up period (Primary outcome). GEE analyses were used to determine mean differences over time of estimated
Glomerular Filtration Rate (eGFR) between intervention group and control group during the follow-up period
Table 2 Mean levels of clinical outcomes, laboratory parameters, and medications between intervention group and control group
Variables Mean level during follow-up Mean difference
(coefficient)
95% CI P-value
Control (n = 208) Intervention (n = 234)
BMI (kg/m2) 24.8 ± 0.2 24.9 ± 0.2 0.49 (−0.3)–1.2 0.22
eGFR (CKD-EPI, ml/min/1.73 m2) 39.9 ± 2.8 42.4 ± 1.5 2.74 0.7–4.8 0.009
Serum Creatinine (mg/dl) 1.6 ± 0.1 1.5 ± 0.1 −0.10 (−0.2)–(−0.02) 0.02
Systolic BP (mmHg) 120 ± 2.3 125 ± 1.9 5.37 3.4–7.3 0.01
Diastolic BP (mmHg) 73 ± 1.3 74 ± 1.8 1.23 0.3–2.2 0.01
Hemoglobin (g/dl) 11.3 ± 0.2 11.2 ± 0.3 0.45 0.36 0.42
Serum bicarbonate (mEq/L) 21.5 ± 1.7 24.5 ± 1.1 2.84 2.4–3.3 0.001
HbA1C in diabetics (%) a 7.9 ± 0.4 7.3 ± 0.2 −0.57 (−0.9)–(−0.2) 0.001
LDL-C (mg/dL) 108 ± 5 107 ± 16 −1.09 (−5.6)–3.4 0.63
Triglyceride (mg/dL) 209 ± 22 192 ± 15 −18.15 (−35.5)–(−0.8) 0.04
Urine protein-creatinine ratio (mg/g) 260 ± 84 336 ± 55 11.42 (−97)–119 0.84
24-h urine Na (mg/day) a 3682 ± 635 2931 ± 309 −739.0 (−1136)–(−343) 0.001
24-h urine nPNA (g/kg/day) 0.91 ± 0.1 0.84 ± 0.02 0.10 (−0.2)–(0.001) 0.049
GEE analyses were used to determine mean differences over time of clinical outcomes and laboratory parameters between the two groups
Data was shown as means (standard deviation) for continuous variables
Abbreviations: GEE generalized estimating equation
aDiffrences already exist at baseline
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finding is consistent with the finding of a randomized
controlled trial which Goraya N, et al. demonstrated that
treatment of metabolic acidosis in patients with stage 3
chronic kidney disease with fruits and vegetables or oral
bicarbonate reduces urine angiotensinogen and pre-
serves glomerular filtration rate [25, 26].
To our knowledge, even if the mean levels over time
of HbA1c, triglycerides, PNA, and urine Na of the inter-
vention group were lower, it is still unclear whether
these factors affected the rate of eGFR decline as there
were baseline differences among these variables. Based
on an assumption that the longitudinal data analysis
(GEE) might offset the baseline differences, these better-
looking secondary outcomes might be implied that inter-
vention could improve compliance with proper dietary
protein and sodium intake and medication.
Importantly, increasing CKD awareness is another
possible explanation why the integrated care could affect
CKD treatment outcomes. In 2009, a population-based





Fig. 3 Changes in clinical and laboratory parameters during the follow-up period. GEE analyses were used to determine mean differences over
time of clinical outcomes and laboratory parameters between the two groups. Change in systolic BP (a), diastolic BP (b), hemoglobin A1C (c),
serum bicarbonate (d), serum triglyceride (e), urine protein-creatinine ratio (f), 24-h urine normalized protein nitrogen appearance (g), 24-h urine
sodium (h) between intervention group and control group during the follow-up period
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Early Evaluation of Kidney Disease (SEEK) study, re-
vealed that only 1.9% of the 3459 participants were
aware that they had CKD prior to the commencement
of the screening program. As our intervention was ‘tai-
lored’ to each patient, sustainable change of patient’s
awareness and behaviors that affect renal and cardiovas-
cular conditions could be anticipated [5, 28].
The collaborative effort between MDCT and CCN was
the critical component of the intervention used in this
study. While MDCT provided standard medical treat-
ment using standard clinical guidelines and essential
knowledge to CKD patients using live demonstration
group counseling during each hospital visit, CCN played
important roles in monitoring compliance to medication,
diet control, blood pressure, and exercise behavior dur-
ing a series of home visits at 6–8 weeks after each
hospital encounter. We also saw the benefits of detailed
discussion about some clinical parameters between the
patient, his or her colleagues, and the CCN team mem-
bers in a cozy environment. Clinical information was
conveyed in a friendly way and questions could be
addressed specifically to each patient in layperson terms,
under supervision of healthcare providers. This ap-
proach is critical, especially when the majority of the
CKD patients are not well educated. Healthcare pro-
viders also had a better understanding of living condi-
tions and social dynamics of the community, which
could affect the progression of CKD as well as other
comorbidities.
This concerted approach might help explain possible
mechanisms of the renal protective effect and the com-
posite renal end points amongst patients in the interven-
tion group. Evidence from clinical trials conducted in
developed countries revealed satisfactory cardiovascular
and renal outcomes from having multidisciplinary care
in hospital settings [7–9]. However, the intervention is
not feasible and the findings therefore could not be gen-
eralized to developing countries where most of CKD
patients lived in rural areas where specialized personnel
is scarce and physician-to-patient contact time is limited
[29]. While the best hospital-based CKD care is not
equally available, we demonstrated that an optimal yet
comprehensive set of harmonized efforts between
healthcare providers and non-healthcare members is
feasible and could yield similar, if not superior, clinical
benefits. The implementation of the integrated CKD
care model in developing countries is feasible. The use
of community volunteers has been identified as one
Table 3 Percentage of medication during the follow-up period
Medications At baseline P-value At the end of study P-value
Control Intervention Control Intervention
(n = 208) (n = 234) (n = 184) (n = 203)
Mean of number of antihypertensive medications 2.0 ± 0.5 2.2 ± 0.4 0.06 1.8 ± 0.4 2.7 ± 0.5 0.05
Mean of number of glucose-lowering medications 0.8 ± 0.2 1.1 ± 0.3 0.08 0.6 ± 0.1 1.7 ± 0.3 0.24
Insulin (%) 16.9 21.1 0.10 16.9 28.4 0.01
ACEi/ARBs use (%) 91.3 85 0.05 88.9 92.7 0.09
Statins use (%) 75.5 71.4 0.33 75 82.9 0.11
Antiplatelets use (%) 63.9 36.3 0.05 55.8 36.3 0.12
NSAIDs (%) 15.4 19.2 0.09 6.5 7.7 0.18
Data was shown as percent for categorical variables and compared using Chi-square test (of Fisher’s exact test)
Abbreviation: ACEi/ARBs Angiotensin Converting Enzyme inhibitors/Angiotensin Receptor Blockers, NSAIDs Non-steroidal Anti-inflammatory Drugs
Table 4 Incidence of Clinical Endpoints (Cox regression analysis)a
Clinical outcome Control (n = 208) Intervention (n = 234) P-value Hazard
ratio
95%CI
No. of events Person-years No. of events Person-years
All-cause mortality 4 387.8 5 449.6 0.92 1.07 0.29–3.90
CV eventsb 4 384.0 2 448.6 0.33 0.43 0.08–2.34
ESRDc 14 370.5 8 439.6 0.11 0.49 0.21–1.16
50% increase in serum Cr from baseline 31 359.5 23 426.8 0.10 0.64 0.37–1.09
Composite clinical endpointsd 41 344.3 29 417.6 0.03 0.59 0.37–0.96
Data was analyzed by using Cox proportional-hazard model based on intention to treat basis
Abbreviation: CV events cardiovascular events
aIn this analysis, data were censored at the date of death, the date of last visit of patients who loss to follow-up or withdrew from the study
bCV events in this analysis are consisted of acute myocardial infarction and stroke
cEnd-stage renal disease (ESRD) is defined as eGFR < 15 ml/min/1.73 m2
dComposite of clinical endpoints in this study is composed of CV events, ESRD, 50% increase in serum creatinine from baseline
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strategy to address the growing shortage of health
workers, particularly in low-income countries. To our
knowledge, the VHV scheme or Community Health
Workers program has been established in more than 20
countries such as India, Brasil, Ethiopia, Kenya, etc. [30].
Furthermore, there is demonstrated evidence that a
multifaceted intervention represents good value for
money as it reduced costs but not quality of life for
CKD patients (CanPREVENT study) [31].
With regard to the study which has been described
above, there are some inevitable limitations. First, a cluster
randomized control trial was chosen over a conventional
double-blinded randomized control trial to account for
the way service delivery was offered so it was possible for
patients in the control group who reside in an overlapping
area to be exposed to activities offered to the intervention
group and vice versa. However, such phenomenon was be-
lieved to be minimal. Second, despite the randomization,
there were several differences of baseline values including
HbA1c, serum triglycerides, 24-h urine sodium and
normalized Protein Nitrogen Appearance (nPNA), which
could affect rate of eGFR decline. However, with the
comparison of mean levels over time, the differences of
baseline parameters may be offset. Lastly, distinguishing
isolated effects of each component of our comprehensive
set of interventions was difficult and therefore introduced
some challenges to generalization of our findings to other
settings that do not have the key CCN components.
Conclusions
In summary, the ESCORT study, a community-based,
cluster randomized controlled study of 442 stage 3-4
CKD patients with a mean follow-up duration 2 years,
shows that integrated CKD care may slow the rate of
eGFR decline significantly and seems to improve the
number of composite clinical events.
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